Quiescent hypervascularity mediated by gain of HIF-1α function

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 67, Issue , 2002, Pages 133-142

  Arbeit, J M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HELIX LOOP HELIX PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR 164; VASCULOTROPIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANGIOGENESIS; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CONFERENCE PAPER; EDEMA; GENE THERAPY; HEMATOPOIESIS; HUMAN; HYPOXIA; LIMB ISCHEMIA; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STEM CELL; VASCULARIZATION; ARTICLE; BLOOD VESSEL PERMEABILITY; HYPOXEMIA;

EID: 0038463624     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2002.67.133     Document Type: Conference Paper

References (96)

1. Alfranca A., Gutierrez M.D., Vara A., Aragones J., Vidal F., and Landazuri M.O. 2002. c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol. Cell. Biol. 22: 12.
2. Benezra R., Rafii S., and Lyden D. 2001. The Id proteins and angiogenesis. Oncogene 20: 8334.
3. Berra E., Milanini J., Richard D.E., Le Gall M., Vinals F., Gothie E., Roux D., Pages G., and Pouyssegur J. 2000. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol. 60: 1171.
4. Boucher Y., Leunig M., and Jain R.K. 1996. Tumor angiogenesis and interstitial hypertension. Cancer Res. 56: 4264.
5. Brown J.M. and Giaccia A.J. 1998. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 58: 1408.
6. Bruick R.K. and McKnight S.L. 2001. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337.
7. Carmeliet P. and Jain R. 2000. Angiogenesis in cancer and other diseases. Nat. Cell Biol. 407: 249.
8. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Chamock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., and Persico M.G. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7: 575.
9. Cockman M., Masson N., Mole D., Jaakkola P., Chang G., Clifford S., Maher E., Pugh C., Ratcliffe P., and Maxwell P. 2000. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275: 25733.
10. Coussens L.M. and Werb Z. 2002. Inflammation and cancer. Nature 420: 860.
11. Coussens L.M., Raymond W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., Caughey G., and Hanahan D. 1999. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13: 1382.
12. Davis S. and Yancopoulos G.D. 1999. The angiopoietins: Yin and yang in angiogenesis. Curr. Top. Microbiol. Immunol. 237: 173.
13. Detmar M., Brown L., Schon M., Elicker B., Velasco P., Richard L., Fukumura D., Monsky W., Claffey K., and Jain R. 1998. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Investig. Dermatol. 111: 1.
14. Dvorak A.M. and Feng D. 2001. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J. Histochem. Cytochem. 49: 419.
15. Dvorak H.F. 2000. VPF/VEGF and the angiogenic response. Semin. Perinatol. 24: 75.
16. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., and Cheresh D.A. 1999. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4: 915.
17. Eliceiri B.P., Puente X.S., Hood J.D., Stupack D.J., Schlaepfer D.D., Huang X.Z., Sheppard D., and Cheresh D.A. 2002. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J. Cell Biol. 157: 149.
18. Elkins J.M., Hewitson K.S., McNeill L.A., Seibel J.F., Schlemminger I., Pugh C.W., Ratcliffe P.J., and Schofield C.J. 2003. Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha. J. Biol. Chem. 278: 1802.
19. Elson D.A., Ryan H.E., Snow J.W., Johnson R., and Arbeit J.M. 2000. Coordinate up-regulation of hypoxia inducible factor (HIF)-1α and HIF-1 target genes during multi-stage carcinogenesis and wound healing. Cancer Res. 60: 6189.
20. Elson D.A., Thurston G., Huang L.E., Ginzinger D.G., McDonald D.M., Johnson R.S., and Arbeit J.M. 2001. Induction of hypervascularity without leak or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev. 15: 2520.
21. Epstein S.E., Komowski R., Fuchs S., and Dvorak H.F. 2001a. Angiogenesis therapy: Amidst the hype, the neglected potential for serious side effects. Circulation 104: 115.
22. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., and Ratcliffe P.J. 2001b. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43.
23. Feng D., Nagy J.A., Pyne K., Hammel I., Dvorak H.F., and Dvorak A.M. 1999. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6: 23.
24. Ferrara N. 1999. Vascular endothelial growth factor: Molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237: 1.
25. -. 2001. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280: C1358.
26. -. 2002. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin. Oncol. 29: 10.
27. Freedman S.B. and Isner J.M. 2001. Therapeutic angiogenesis for ischemic cardiovascular disease. J. Mol. Cell. Cardiol. 33: 379.
28. Freedman S.J., Sun Z.Y., Poy F., Kung A.L., Livingston D.M., Wagner G., and Eck M.J. 2002. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc. Natl. Acad. Sci. 99: 5367.
29. Gill M., Dias S., Hattori K., Rivera M.L., Hicklin D., Witte L., Girardi L., Yurt R., Himel H., and Rafii S. 2001. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res. 88: 167.
30. Grunstein J., Masbad J., Hickey R., Giordano F., and Johnson R. 2000. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol. Cell. Biol. 20: 7282.
31. Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., and Giaccia A.J. 2002. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22: 1834.
32. Hara S., Hamada J., Kobayashi C., Kondo Y., and Imura N. 2001. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: Suppression of HIF-mediated gene expression by HIF-3alpha. Biochem. Biophys. Res. Commun. 287: 808.
33. Hattori K., Heissig B., Wu Y., Dias S., Tejada R., Ferris B., Hicklin D.J., Zhu Z., Bohlen P., Witte L., Hendrikx J., Hackett N.R., Crystal R.G., Moore M.A., Werb Z., Lyden D., and Rafii S. 2002. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8: 841.
34. Heissig B., Hattori K., Friedrich M., Rafii S., and Werb Z. 2003. Angiogenesis: Vascular remodeling of the extracellular matrix involves metalloproteinases. Curr. Opin. Hematol. 10: 136.
35. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., Crystal R.G., Besmer P., Lyden D., Moore M.A., Werb Z., and S. Rafii S. 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109: 625.
36. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. 95: 7987.
37. Hudson C.C., Liu M., Chiang G.G., Ottemess D.M., Loomis D.C., Kaper F., Giaccia A.J., and Abraham R.T. 2002. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22: 7004.
38. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., and Neckers L.M. 2002. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277: 29936.
39. 2 sensing. Science 292: 464.
40. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12: 149.
41. 2-regulated prolyl hydroxylation. Science 292: 468.
42. Jain R.K. 2001. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 7: 987.
43. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., and Kim K.W. 2002. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709.
44. Jiang B.H., Zheng J.Z., Leung S.W., Roe R, and Semenza G.L. 1997. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. J. Biol. Chem. 272: 19253.
45. Jin N., Hatton N., Swartz D.R., Xia X., Harrington M.A., Larsen S.H., and Rhoades R.A. 2000. Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am. J. Respir. Cell Mol. Biol. 23: 593.
46. Kaelin W.G., Jr. and Maher E.R. 1998. The VHL tumour-suppressor gene paradigm. Trends Genet. 14: 423.
47. Karni R., Dor Y., Keshet E., Meyuhas O., and Levitzki A. 2002. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J. Biol. Chem. 277: 42919.
48. Kawamoto A., Gwon H.C., Iwaguro H., Yamaguchi J.I., Uchida S., Masuda H., Silver M., Ma H., Kearney M., Isner J.M., and Asahara T. 2001. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103: 634.
49. Kim W. and Kaelin W.G. 2003. The von Hippel-Lindau tumor suppressor protein: New insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13: 55.
50. Koh G.Y., Kim I., Kwak H.J., Yun M.J., and Leem J.C. 2002. Biomedical significance of endothelial cell specific growth factor, angiopoietin. Exp. Mol. Med. 34: 1.
51. Koumenis C., Alarcon R., Hammond E., Sutphin P., Hoffman W., Murphy M., Derr J., Taya Y., Lowe S.W., Kastan M., and Giaccia A. 2001. Regulation of p53 by hypoxia: Dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell. Biol. 21: 1297.
52. Krishnamachary B., Berg-Dixon S., Kelly B., Agani F., Feldser D., Ferreira G., Iyer N., LaRusch J., Pak B., Taghavi P., and Semenza G. 2003. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63: 1138.
53. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. 2002. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16: 1466.
54. Larcher F., Murillas R., Bolontrade M., Conti C.J., and Jorcano J.L. 1998. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17: 303.
55. Lee C., Kim S.J., Jeong D.G., Lee S.M., and Ryu S.E. 2003. Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J. Biol. Chem. 278: 7558.
56. Lee R., Springer M., Blanco-Bose W., Shaw R., Ursell P., and Blau H. 2000. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 102: 898.
57. Luttun A., Tjwa M., and Carmeliet P. 2002a. Placental growth factor (P1GF) and its receptor Flt-1 (VEGFR-1): Novel therapeutic targets for angiogenic disorders. Ann. N.Y. Acad. Sci. 979: 80.
58. Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., Nagy J.A., Hooper A., Priller J., De Klerck B., Compernolle V., Daci E., Bohlen P., Dewerchin M., Herbert J.M., Fava R., Matthys P., Carmeliet G., Collen D., Dvorak H.F., Hicklin D.J., and Carmeliet P. 2002b. Revascularization of ischemic tissues by P1GF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8: 831.
59. Mahon P.C., Hirota K., and Semenza G.L. 2001. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15: 2675.
60. Maltepe E., Schmidt J.V., Baunoch D., Bradfield C.A., and Simon M.C. 1997. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386: 403.
61. Maxwell P., Wiesener M., Chang G., Clifford S., Vaux E., Cockman M., Wykoff C., Pugh C., Maher E., and Ratcliffe P. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271.
62. McNeill L.A., Hewitson K.S., Gleadle J.M., Horsfall L.E., Oldham N.J., Maxwell P.H., Pugh C.W., Ratcliffe P.J., and Schofield C.J. 2002. The use of dioxygen by HIF prolyl hydroxylase (PHD1). Bioorg. Med. Chem. Lett. 12: 1547.
63. Min J.H., Yang H., Ivan M., Gertler F., Kaelin W.G., Jr., and Pavletich N.P. 2002. Structure of an HIF-1alpha-pVHL complex: Hydroxyproline recognition in signaling. Science 296: 1886.
64. Odorisio T., Schietroma C., Zaccaria M.L., Cianfarani F., Tiveron C., Tatangelo L., Failla C.M., and Zambruno G. 2002. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J. Cell Sci. 115: 2559.
65. Oh H., Takagi H., Suzuma K., Otani A., Matsumura M., and Honda Y. 1999. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. 274: 15732.
66. Ohh M., Park C., Ivan M., Hoffman M., Kim T., Huang L., Pavletich N., Chau V., and Kaelin W. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2: 423.
67. Paul R., Zhang Z.G., Eliceiri B.P., Jiang Q., Boccia A.D., Zhang R.L., Chopp M., and Cheresh D.A. 2001. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med. 7: 222.
68. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., Oz M.C., Hicklin D.J., Witte L., Moore M.A., and Rafii S. 2000. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95: 952.
69. Premkumar D.R., Adhikary G., Overholt J.L., Simonson M.S., Cherniack N.S., and Prabhakar N.R. 2000. Intracellular pathways linking hypoxia to activation of c-fos and AP-1. Adv. Exp. Med. Biol. 475: 101.
70. Rafii S. 2000. Circulating endothelial precursors: Mystery, reality, and promise. J. Clin. Invest. 105: 17.
71. Rafii S., Lyden D., Benezra R., Hattori K., and Heissig B. 2002a. Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2: 826.
72. Rafii S., Meeus S., Dias S., Hattori K., Heissig B., Shmelkov S., Rafii D., and Lyden D. 2002b. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin. Cell Dev. Biol. 13: 61.
73. Rebar E.J., Huang Y., Hickey R., Nath A.K., Meoli D., Nath S., Chen B., Xu L., Liang Y., Jamieson A.C., Zhang L., Spratt S.K., Case C.C., Wolffe A., and Giordano F.J. 2002. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med. 8: 1427.
74. Royds J.A., Dower S.K., Qwarnstrom E.E., and Lewis C.E. 1998. Response of tumour cells to hypoxia: Role of p53 and NFκB. Mol. Pathol. 51: 55.
75. Ryan H., Lo J., and Johnson R. 1998. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17: 3005.
76. Ryan H., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J., and Johnson R. 2000. Hypoxia-inducible factor-1 alpha is a positive factor in solid tumor growth. Cancer Res. 60: 4010.
77. Salceda S. and Caro J. 1997. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272: 22642.
78. Schipani E., Ryan H.E., Didrickson S., Kobayashi T., Knight M., and Johnson R.S. 2001. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev. 15: 2865.
79. Semenza, G.L. 2000. Surviving ischemia: Adaptive responses mediated by hypoxia-inducible factor 1. J. Clin. Invest. 106: 809.
80. -. 2002. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64: 993.
81. -. 2003. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 54: 17.
82. Shyu K.-G., Wang M.-T., Wang B.-W., Chang C.-C., Leu J.-G., Kuan P., and Chang H. 2002. Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc. Res. 54: 576.
83. Springer M., Chen A., Kraft P., Bednarski M., and Blau H. 1998. VEGF gene delivery to muscle: Potential role for vasculogenesis in adults. Mol. Cell 2: 549.
84. Sundberg C., Nagy J.A., Brown L.F., Feng D., Eckelhoefer I.A., Manseau E.J., Dvorak A.M., and Dvorak H.F. 2001. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am. J. Pathol. 158: 1145.
85. Suri C., McClain J., Thurston G., McDonald D., Zhou H., Oldmixon E., Sato T., and Yancopoulos G. 1998. Increased vascularization in mice overexpressing angiopoietin-1. Science 282: 468.
86. Talks K., Turley H., Gatter K., Maxwell P., Pugh C., Ratcliffe P., and Harris A. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157: 411.
87. Thurston G., Suri C., Smith K., McClain J., Sato T., Yancopoulos G.D., and McDonald D. 1999. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286: 2511.
88. Thurston G., Rudge J.S., Ioffe E., Zhou H., Ross L., Croll S., Glazer N., Holash J., McDonald D., and Yancopoulos G.D. 2000. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6: 460.
89. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., and McKnight S.L. 1998. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12: 3320.
90. Vincent K., Shyu K., Luo Y., Magner M., Tio R., Jiang C., Gopldberg M., Akita G., Gregory R., and Isner J. 2000. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/VP16 hybrid transcription factor. Circulation 102: 2255.
91. Yan S.F., Fujita T., Lu J., Okada K., Shan Zou Y., Mackman N., Pinsky D.J., and Stern D.M. 2000. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat. Med. 6: 1355.
92. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407: 242.
93. Yang H. and Kaelin W.G., Jr. 2001. Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: Implications for oxygen sensing. Cell Growth Differ. 12: 447.
94. Yurasov S.V., Flasshove M., Rafii S., and Moore M.A. 1996. Density enrichment and characterization of hematopoietic progenitors and stem cells from umbilical cord blood. Bone Marrow Transplant. 17: 517.
95. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., and Semenza G.L. 2000. Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer 88: 2606.
96. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A., Ryan H., Johnson R., Jefferson A., Stokoe D., and Giaccia A. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14: 391.